Matches in SemOpenAlex for { <https://semopenalex.org/work/W3190868265> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W3190868265 abstract "Real-world assessments of biosimilars are needed to understand their effectiveness and safety in practice settings that may differ from those seen in clinical trials or healthcare systems in different countries. To assess the effectiveness and safety of a biosimilar (infliximab-dyyb) and its reference product (infliximab) in patients with inflammatory bowel disease (IBD) in the United States.We conducted a retrospective cohort study of biologic-naive patients with IBD who started treatment with infliximab-dyyb or infliximab. The study included 3206 patients identified through electronic health records in a US integrated healthcare delivery system. The effectiveness outcome was a composite of IBD-related surgery, IBD-related emergency room visit, and IBD-related hospitalization within 12 months of initiation. Safety outcomes included incidence of any or serious infection, cancer, acute liver dysfunction, and tuberculosis. We used a non-inferiority test with an upper-limit margin of 10% to analyze effectiveness. Doubly robust methods incorporating Cox proportional hazard regression with standardized inverse probability of treatment weighting were used to analyze both effectiveness and safety outcomes.The composite effectiveness outcome occurred in 107 of 870 patients (12.3%) in the infliximab-dyyb and 379 of 2336 patients (16.2%) in the infliximab groups. Infliximab-dyyb was non-inferior (P < .01) and was not different (hazard ratio [HR] 0.81; confidence interval [CI] 0.65-1.01; P = .06) to infliximab. Safety outcomes were not different between infliximab-dyyb and infliximab for any infections (HR 1.01; CI 0.86-1.17; P = .95), serious infections (HR 0.83; CI 0.54-1.26; P = .38), cancers (HR 0.83; CI 0.44-1.54; P = .55), and tuberculosis (HR 0.59; CI 0.10-3.55; P = .57).Initiation of infliximab-dyyb was non-inferior to infliximab among biologic-naive patients with IBD in an US integrated healthcare delivery system." @default.
- W3190868265 created "2021-08-16" @default.
- W3190868265 creator A5001051673 @default.
- W3190868265 creator A5021741152 @default.
- W3190868265 creator A5043116308 @default.
- W3190868265 creator A5056210366 @default.
- W3190868265 creator A5071164015 @default.
- W3190868265 creator A5071842426 @default.
- W3190868265 creator A5081770490 @default.
- W3190868265 creator A5087901835 @default.
- W3190868265 date "2021-07-01" @default.
- W3190868265 modified "2023-09-23" @default.
- W3190868265 title "Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States" @default.
- W3190868265 cites W2034772721 @default.
- W3190868265 cites W2036193982 @default.
- W3190868265 cites W2064691418 @default.
- W3190868265 cites W2121050884 @default.
- W3190868265 cites W2150291618 @default.
- W3190868265 cites W2162768160 @default.
- W3190868265 cites W2167609288 @default.
- W3190868265 cites W2578994901 @default.
- W3190868265 cites W2590018687 @default.
- W3190868265 cites W2613299853 @default.
- W3190868265 cites W2767910653 @default.
- W3190868265 cites W2797152839 @default.
- W3190868265 cites W2898471151 @default.
- W3190868265 cites W2904014975 @default.
- W3190868265 cites W2921749306 @default.
- W3190868265 cites W2923675504 @default.
- W3190868265 cites W2945299140 @default.
- W3190868265 cites W2989858130 @default.
- W3190868265 cites W3000625420 @default.
- W3190868265 cites W3006941864 @default.
- W3190868265 cites W3022365662 @default.
- W3190868265 doi "https://doi.org/10.1093/crocol/otab051" @default.
- W3190868265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36776661" @default.
- W3190868265 hasPublicationYear "2021" @default.
- W3190868265 type Work @default.
- W3190868265 sameAs 3190868265 @default.
- W3190868265 citedByCount "0" @default.
- W3190868265 crossrefType "journal-article" @default.
- W3190868265 hasAuthorship W3190868265A5001051673 @default.
- W3190868265 hasAuthorship W3190868265A5021741152 @default.
- W3190868265 hasAuthorship W3190868265A5043116308 @default.
- W3190868265 hasAuthorship W3190868265A5056210366 @default.
- W3190868265 hasAuthorship W3190868265A5071164015 @default.
- W3190868265 hasAuthorship W3190868265A5071842426 @default.
- W3190868265 hasAuthorship W3190868265A5081770490 @default.
- W3190868265 hasAuthorship W3190868265A5087901835 @default.
- W3190868265 hasBestOaLocation W31908682651 @default.
- W3190868265 hasConcept C126322002 @default.
- W3190868265 hasConcept C167135981 @default.
- W3190868265 hasConcept C207103383 @default.
- W3190868265 hasConcept C2777138892 @default.
- W3190868265 hasConcept C2778260677 @default.
- W3190868265 hasConcept C2779134260 @default.
- W3190868265 hasConcept C44249647 @default.
- W3190868265 hasConcept C71924100 @default.
- W3190868265 hasConcept C72563966 @default.
- W3190868265 hasConceptScore W3190868265C126322002 @default.
- W3190868265 hasConceptScore W3190868265C167135981 @default.
- W3190868265 hasConceptScore W3190868265C207103383 @default.
- W3190868265 hasConceptScore W3190868265C2777138892 @default.
- W3190868265 hasConceptScore W3190868265C2778260677 @default.
- W3190868265 hasConceptScore W3190868265C2779134260 @default.
- W3190868265 hasConceptScore W3190868265C44249647 @default.
- W3190868265 hasConceptScore W3190868265C71924100 @default.
- W3190868265 hasConceptScore W3190868265C72563966 @default.
- W3190868265 hasIssue "3" @default.
- W3190868265 hasLocation W31908682651 @default.
- W3190868265 hasLocation W31908682652 @default.
- W3190868265 hasLocation W31908682653 @default.
- W3190868265 hasOpenAccess W3190868265 @default.
- W3190868265 hasPrimaryLocation W31908682651 @default.
- W3190868265 hasRelatedWork W1516595110 @default.
- W3190868265 hasRelatedWork W1548660409 @default.
- W3190868265 hasRelatedWork W1984976117 @default.
- W3190868265 hasRelatedWork W2022117977 @default.
- W3190868265 hasRelatedWork W2297514571 @default.
- W3190868265 hasRelatedWork W2490521022 @default.
- W3190868265 hasRelatedWork W2576474053 @default.
- W3190868265 hasRelatedWork W3130241389 @default.
- W3190868265 hasRelatedWork W4310702849 @default.
- W3190868265 hasRelatedWork W4318576021 @default.
- W3190868265 hasVolume "3" @default.
- W3190868265 isParatext "false" @default.
- W3190868265 isRetracted "false" @default.
- W3190868265 magId "3190868265" @default.
- W3190868265 workType "article" @default.